| Year |
Title |
Altmetric |
| 2021
|
Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.
Breast Cancer Research.
23.
2021
|
|
| 2021
|
Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53.
Clinical Cancer Research.
27:5236-5247.
2021
|
|
| 2021
|
Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women.
Translational Oncology.
14.
2021
|
|
| 2021
|
Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.
British Journal of Haematology.
2021
|
|
| 2020
|
First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern Oncotherapeutics.
Scientific Reports.
10.
2020
|
|
| 2020
|
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings
2020
|
|
| 2020
|
Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians.
Contemporary Clinical Trials Communications.
19.
2020
|
|
| 2020
|
First-In-Human Phase 1 Clinical Trials - A Single-Center Experience In The Era Of Modern Oncotherapeutics.
Scientific Reports.
10:7935-7935.
2020
|
|
| 2020
|
TBCRC 002: A phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Breast Cancer Research.
22.
2020
|
|
| 2019
|
Bridging the Gap in Training and Clinical Practice in Sub-Saharan Africa.
Current Breast Cancer Reports.
11:158-169.
2019
|
|
| 2019
|
Promoting Breast Cancer Awareness and Clinical Breast Examination in the LMIC: Experiences from Tajikistan, Pakistan and Kenya.
Current Breast Cancer Reports.
11:152-157.
2019
|
|
| 2019
|
Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at O'Neal Comprehensive Cancer Center.
Annals of Oncology.
30:iv66.
2019
|
|
| 2019
|
Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study.
Annals of Oncology.
30:iv124.
2019
|
|
| 2019
|
Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Cancer Chemotherapy and Pharmacology.
83:551-559.
2019
|
|
| 2019
|
Breast Cancer knowledge, perceptions and practices in a rural Community in Coastal Kenya.
BMC Public Health.
19.
2019
|
|
| 2019
|
Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.
American Journal of Hematology.
94:200-208.
2019
|
|
| 2018
|
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
Nature Communications.
9.
2018
|
|
| 2018
|
So You want to be a principal investigator.
Journal of Oncology Practice.
14:e384-e392.
2018
|
|
| 2018
|
Promoting clinical breast evaluations in a lower middle-income country setting: An approach toward achieving a sustainable breast health program.
Journal of Global Oncology.
2018:1-8.
2018
|
|
| 2018
|
Ethnicity and breast cancer characteristics in Kenya.
Breast Cancer Research and Treatment.
167:425-437.
2018
|
|
| 2018
|
Nano and microbubble systems for on-demand cancer drug delivery.
Current Nanoscience.
14:33-41.
2018
|
|
| 2017
|
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study.
Blood.
130:2527-2536.
2017
|
|
| 2017
|
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Annals of Oncology.
28:2264-2271.
2017
|
|
| 2017
|
Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone.
Clinical Cancer Research.
23:3544-3551.
2017
|
|
| 2017
|
Academic cancer center phase i program development
2017
|
|
| 2016
|
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
2016
|
|
| 2016
|
Breast camps for awareness and early diagnosis of breast cancer in countries with limited resources: A multidisciplinary model from Kenya
2016
|
|
| 2016
|
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.
Cancer Chemotherapy and Pharmacology.
78:509-515.
2016
|
|
| 2016
|
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Annals of Oncology.
27:1041-1047.
2016
|
|
| 2016
|
A community-oriented approach to breast cancer in a low-resource setting: Improving awareness, early detection and treatment of breast cancer in Tajikistan
2016
|
|
| 2015
|
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Cancer Chemotherapy and Pharmacology.
76:949-955.
2015
|
|
| 2015
|
SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer.
Clinical Colorectal Cancer.
14:72-80.
2015
|
|
| 2015
|
EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB - Expressing breast cancer.
Journal of Clinical Oncology.
33:1609-1619.
2015
|
|
| 2014
|
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Journal of Clinical Oncology.
32:3840-3847.
2014
|
|
| 2014
|
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
Journal of Clinical Oncology.
32:3619-3625.
2014
|
|
| 2014
|
Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya
2014
|
|
| 2014
|
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Clinical Cancer Research.
20:3581-3588.
2014
|
|
| 2014
|
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
Annals of Oncology.
25:1416-1421.
2014
|
|
| 2014
|
A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.
Cancer Medicine.
3:988-997.
2014
|
|
| 2014
|
Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting.
Current Medical Research and Opinion.
30:529-536.
2014
|
|
| 2014
|
Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.
Supportive Care in Cancer.
22:1833-1841.
2014
|
|
| 2013
|
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
Clinical Colorectal Cancer.
12:218-222.
2013
|
|
| 2013
|
Breast cancer diagnosis in a resource poor environment through a collaborative multidisciplinary approach: The Kenyan experience.
Journal of Clinical Pathology.
66:307-311.
2013
|
|
| 2013
|
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
British Journal of Haematology.
160:538-546.
2013
|
|
| 2013
|
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study.
Blood.
121:537-545.
2013
|
|
| 2013
|
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
New England Journal of Medicine.
369:1691-1703.
2013
|
|
| 2013
|
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: A phase I study.
British Journal of Haematology.
162:693-701.
2013
|
|
| 2013
|
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Cancer Medicine.
2:925-932.
2013
|
|
| 2013
|
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study
2013
|
|
| 2012
|
Therapeutic optimization of aromatase inhibitor-associated arthralgia: Etiology, onset, resolution, and symptom management in early breast cancer.
Community Oncology.
9:94-102.
2012
|
|
| 2012
|
Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Clinical Cancer Research.
18:1092-1100.
2012
|
|
| 2011
|
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Journal of Clinical Oncology.
29:3877-3884.
2011
|
|
| 2011
|
Abiraterone and increased survival in metastatic prostate cancer.
New England Journal of Medicine.
364:1995-2005.
2011
|
|
| 2011
|
Eltrombopag for chronic immune thrombocytopenia - Authors' reply
2011
|
|
| 2011
|
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study
2011
|
|
| 2011
|
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402))
2011
|
|
| 2011
|
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial.
Clinical Breast Cancer.
11:82-92.
2011
|
|
| 2010
|
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Clinical Breast Cancer.
10:281-287.
2010
|
|
| 2010
|
Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer.
Clinical Breast Cancer.
10:275-280.
2010
|
|
| 2010
|
A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.
Cancer Investigation.
28:208-215.
2010
|
|
| 2010
|
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).
Cancer Biotherapy and Radiopharmaceuticals.
25:13-19.
2010
|
|
| 2010
|
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.
Journal of Thoracic Oncology.
5:1977-1985.
2010
|
|
| 2009
|
Analysis of the impact and burden of illness of adult chronic ITP in the US.
Current Medical Research and Opinion.
25:2961-2969.
2009
|
|
| 2009
|
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
Journal of Clinical Oncology.
27:5023-5030.
2009
|
|
| 2009
|
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses.
Journal of Clinical Oncology.
27:4754-4759.
2009
|
|
| 2009
|
A randomized, phase II trial of two dose schedules of carboplatin/ paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
Annals of Oncology.
20:1068-1073.
2009
|
|
| 2009
|
Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting.
Community Oncology.
6:62-67.
2009
|
|
| 2009
|
Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: Results from a community oncology practice.
Community Oncology.
6:257-261.
2009
|
|
| 2007
|
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Investigational New Drugs.
25:565-570.
2007
|
|
| 2007
|
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
New England Journal of Medicine.
357:2237-2247.
2007
|
|
| 2007
|
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators.
Journal of Clinical Oncology.
25:669-674.
2007
|
|
| 2007
|
Bendamustine in non-Hodgkin lymphoma: The double-agent that came from the cold war
2007
|
|
| 2006
|
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Journal of Clinical Oncology.
24:2456-2464.
2006
|
|
| 2005
|
Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer
2005
|
|
| 2005
|
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer.
Journal of Clinical Oncology.
23:9089-9096.
2005
|
|
| 2004
|
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
Journal of Clinical Oncology.
22:1063-1070.
2004
|
|
| 2004
|
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
British Journal of Haematology.
125:470-476.
2004
|
|
| 2003
|
Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story..
Journal of the Medical Association of Georgia.
92:39-46.
2003
|
|
| 2002
|
A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
Clinical Cancer Research.
8:3092-3099.
2002
|
|
| 2002
|
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Journal of Clinical Oncology.
20:3262-3269.
2002
|
|
| 2002
|
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial.
Blood.
99:4336-4342.
2002
|
|
| 2002
|
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma.
Seminars in Oncology.
29:87-92.
2002
|
|
| 2001
|
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer.
Cancer Biotherapy and Radiopharmaceuticals.
16:125-132.
2001
|
|
| 2001
|
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Journal of Clinical Oncology.
19:3918-3928.
2001
|
|
| 2001
|
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
Journal of Clinical Oncology.
19:3234-3243.
2001
|
|
| 2001
|
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
Annals of Oncology.
12:109-114.
2001
|
|
| 2000
|
A pilot study of anti-cd20 moab mtuximab in patients with refractory immune thrombocytopenic purpura (TTP).
Blood.
96.
2000
|
|
| 2000
|
BR96-doxorubicin: Been there, done that! [1] (multiple letters).
Journal of Clinical Oncology.
18:4000.
2000
|
|
| 2000
|
Oral chlorambucil and prednisone with rituximab as initial chemotherapy for low grade non hodgkin's lymphoma: a phase ii trial.
Blood.
96.
2000
|
|
| 2000
|
Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Journal of Clinical Oncology.
18:1316-1323.
2000
|
|
| 2000
|
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors.
Journal of Clinical Oncology.
18:2282-2292.
2000
|
|
| 1999
|
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration.
Clinical Cancer Research.
5:2330-2337.
1999
|
|
| 1999
|
NCCN practice guidelines for Hodgkin's disease
1999
|
|
| 1999
|
Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation.
Cancer Biotherapy and Radiopharmaceuticals.
14:451-463.
1999
|
|
| 1999
|
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
Journal of Clinical Oncology.
17:478-484.
1999
|
|
| 1999
|
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Journal of Clinical Oncology.
17:268-276.
1999
|
|
| 1998
|
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2.
Blood.
91:399-405.
1998
|
|
| 1998
|
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Journal of The American Academy of Dermatology.
39:63-73.
1998
|
|
| 1998
|
Chimeric antibodies with specificity for tumor antigens: Demonstration of in situ localization to tumors after antibody therapy
1998
|
|
| 1998
|
Diphtheria toxin fusion proteins.
Current Topics in Microbiology and Immunology.
234:63-81.
1998
|
|
| 1998
|
Immunologic response to the dual murine anti-id vaccine melimmune-1 and melimmune-2 in patients with high-risk melanoma without evidence of systemic disease.
Journal of Immunotherapy.
21:379-388.
1998
|
|
| 1997
|
A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow.
Human Gene Therapy.
8:157-170.
1997
|
|
| 1997
|
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
Cancer Biotherapy and Radiopharmaceuticals.
12:79-87.
1997
|
|
| 1996
|
Phase Ia/Ib trial of Anti-GD2 chimeric monoclonal antibody 14.18 (ch l4.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
Journal of Immunotherapy.
19:206-217.
1996
|
|
| 1995
|
Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal Cancer.
Cancer Research.
55:4339-4346.
1995
|
|
| 1995
|
CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.
Blood.
85:2910-2917.
1995
|
|
| 1995
|
Phase I trial of an anti-cd19 deglycosylated ricin a chain immunotoxin in non-hodgkin's lymphoma: Effect of an intensive schedule of administration.
Journal of Immunotherapy.
18:231-241.
1995
|
|
| 1993
|
A Phase I Clinical Trial of Murine Monoclonal Antibody D612 in Patients with Metastatic Gastrointestinal Cancer.
Cancer Research.
53:4555-4562.
1993
|
|
| 1993
|
Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
Journal of Immunology.
151:3390-3398.
1993
|
|
| 1992
|
Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody.
Journal of Clinical Immunology.
12:116-121.
1992
|
|
| 1992
|
Advances in monoclonal antibody therapy of cancer.
American Journal of the Medical Sciences.
304:214-224.
1992
|
|
| 1992
|
Monoclonal antibody therapy of cancer
1992
|
|
| 1992
|
Phase I Trial of the Murine Monoclonal Anti-GD2 Antibody 14G2a in Metastatic Melanoma.
Cancer Research.
52:4342-4347.
1992
|
|
| 1992
|
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.
Journal of Nuclear Medicine.
33:23-29.
1992
|
|
| 1992
|
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
Human Antibodies.
3:19-24.
1992
|
|
| 1992
|
Selection of platelets for refractory patients by HLA matching and prospective crossmatching.
Transfusion.
32:633-640.
1992
|
|
| 1991
|
Pharmacokinetics and Immune Response of 131I-ChimericMouse/Human B72.3 (Human 74) Monoclonal Antibody in Humans.
Cancer Research.
51:5461-5466.
1991
|
|
| 1991
|
Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons.
Cancer Research.
51:4155-4163.
1991
|
|
| 1991
|
In-111 labeled monoclonal anti-carcinoembryonic antigen antibody (ZCE025) in the immunoscintigraphic imaging of metastatic antigen-producing adenocarcinomas.
Clinical Nuclear Medicine.
16:110-116.
1991
|
|
| 1991
|
Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody.
Journal of Nuclear Medicine.
32:1162-1168.
1991
|
|
| 1990
|
A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data
1990
|
|
| 1990
|
Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans.
Journal of biological response modifiers.
9:178-184.
1990
|
|
| 1990
|
Intravenous immunoglobulin therapy in systemic lupus erythematosus‐associated thrombocytopenia.
Arthritis and Rheumatism.
33:1233-1239.
1990
|
|
| 1989
|
Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia.
Blood.
73:662-665.
1989
|
|
| 1989
|
Intrathecal cytosine arabinoside-induced acute, rapidly reversible paralysis.
American Journal of Medicine.
86:729-730.
1989
|
|
| 1989
|
Monocyte-platelet interaction in immune and nonimmune thrombocytopenia.
Blood.
74:1328-1331.
1989
|
|
| 1989
|
Quinidine-induced immune thrombocytopenia.
Henry Ford Hospital medical journal.
37:28-32.
1989
|
|
| 1988
|
Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects
1988
|
|
| 1988
|
Phase I trial of multiple large doses of murine monoclonal antibody Co17-1A. II. Pharmacokinetics and immune response
1988
|
|
| 1988
|
Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma.
Journal of Clinical Oncology.
6:1059-1065.
1988
|
|
| 1988
|
Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets.
British Journal of Haematology.
68:47-51.
1988
|
|
| 1987
|
Acute myelofibrosis and multiple chloromas of the mandible and skin.
International Journal of Oral and Maxillofacial Surgery.
16:108-111.
1987
|
|
| 1987
|
Immune thrombocytopenia: Effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG: Case Report.
American Journal of the Medical Sciences.
293:112-118.
1987
|
|
| 1987
|
Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia.
Blood.
69:278-283.
1987
|
|
| 1986
|
Phase I clinical trial of CO17-1A monoclonal antibody.
Hybridoma.
5.
1986
|
|
| 1986
|
In vitro effects of gammaglobulin (IgG) on human monocyte Fc receptor function. I. Effect on monocyte membrane‐associated IgG and Fc receptor‐dependent binding of antibody‐coated platelets.
American Journal of Hematology.
23:197-207.
1986
|
|
